Oct 8, 2026 07:00AM
Oct 8, 2026 07:00AM
Oct 2, 2026 06:57AM
Oct 1, 2026 07:30PM
Oct 1, 2026 07:30PM
Sep 24, 2026 07:02AM
Sep 24, 2026 07:00AM Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Sep 14, 2026 11:05AM
Aug 17, 2026 09:29AM
Aug 12, 2026 07:30PM
Aug 12, 2026 07:30PM
Aug 6, 2026 07:00AM
Jul 28, 2026 07:00AM
Jul 28, 2026 07:00AM Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
May 19, 2026 07:01AM
May 19, 2026 07:00AM
May 18, 2026 08:34AM
May 7, 2026 07:00AM
Apr 28, 2026 07:00AM
Apr 28, 2026 07:00AM
Mar 10, 2026 07:00AM Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Jan 8, 2026 07:05AM
Jan 8, 2026 07:00AM
Dec 8, 2025 10:34AM
Dec 8, 2025 10:31AM
Dec 1, 2025 07:00AM
Dec 1, 2025 07:00AM
Nov 21, 2025 06:40AM Cullinan Oncology Inc. (CGEM) PT Raised to $26 at H.C. Wainwright
Nov 20, 2025 07:13AM
Nov 20, 2025 07:00AM
Nov 6, 2025 07:00AM
Oct 12, 2025 06:27PM
Sep 9, 2025 05:30AM
Aug 21, 2025 06:35AM
Aug 7, 2025 07:00AM Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Jul 22, 2025 07:01AM
Jul 22, 2025 07:00AM
Jun 1, 2025 08:21AM
May 22, 2025 05:15PM
May 8, 2025 07:00AM
Apr 29, 2025 07:03AM
Apr 29, 2025 07:00AM Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
Apr 23, 2025 10:14AM
Apr 16, 2025 07:00AM
Apr 16, 2025 07:00AM
Feb 27, 2025 07:00AM
Jan 30, 2025 06:39AM
Jan 28, 2025 07:00PM
Nov 7, 2024 07:00AM Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 17, 2024 06:54AM

334,491 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All